LATE-BREAKING ABSTRACT: The histone-deacetylase-8 selective inhibitor PCI-34051 enhances IFN-λ production <em>in vitro</em> and reduces inflammation in mouse models of rhinoviral infection and rhinovirus-induced exacerbations of asthma <em>in vivo</em>

LATE-BREAKING ABSTRACT: The histone-deacetylase-8 selective inhibitor PCI-34051 enhances IFN-λ production in vitro and reduces inflammation in mouse models of rhinoviral infection and rhinovirus-induced exacerbations of asthma in vivo

M. Bosnar, G. Ergovic, B. Hrvacic, K. Frka Boric, A. Paravic Radicevic, I. Glojnaric, V. Erakovic Haber (Zagreb, Croatia)

Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment

Session: Hot topics on airway diseases: new horizons in treatment
Session type: Oral Presentation
Number: 1972

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Bosnar, G. Ergovic, B. Hrvacic, K. Frka Boric, A. Paravic Radicevic, I. Glojnaric, V. Erakovic Haber (Zagreb, Croatia). LATE-BREAKING ABSTRACT: The histone-deacetylase-8 selective inhibitor PCI-34051 enhances IFN-λ production in vitro and reduces inflammation in mouse models of rhinoviral infection and rhinovirus-induced exacerbations of asthma in vivo. Eur Respir J 2013; 42: Suppl. 57, 1972

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Targeting PI3Kd attenuates influenza virus-induced inflammation in a murine model of asthma exacerbation Source: International Congress 2017 – Infection and exacerbation science Year: 2017
Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
HDM-challenged mice exhibit impaired interferon response to TLR3 ligand in a murine model of viral asthma exacerbation Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015
LATE-BREAKING ABSTRACT: MUC1 downregulation induces corticosteroid resistance in asthma’s in vitro and in vivo models Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
Inhaled PPAR-r agonist inhibit the airway inflammation in murine model of acute and chronic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 24s Year: 2007
LATE-BREAKING ABSTRACT: IL33 drives humoral and cellular immune response in influenza-induced severe exacerbation of experimental asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation Source: ERS Lung Science Conference 2019 Year: 2019
Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015
Influenza induced exacerbation is associated with steroid insensitive AHR and pulmonary inflammation in HDM-sensitised mice Source: International Congress 2016 – Immune responses in the lung Year: 2016
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Roflumilast inhibits chemokine release in animal models of COPD and asthma Source: Eur Respir J 2004; 24: Suppl. 48, 690s Year: 2004
Selective decoy-mediated inhibition of activator protein-1 activity in the airways prevents experimental asthmatic inflammation Source: Annual Congress 2005 - Regulation of the allergic and asthmatic response Year: 2005
Rapamycin protects OVA induced asthma in mice through regulating autophagy Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015
LATE-BREAKING ABSTRACT: Inhibition of TRPA1 reduces airway inflammation and airway hyper-responsiveness in a murine model of allergic rhinitis Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016
Influence of infection and α1-proteinase inhibitor on inflammatory response in COPD exacerbation Source: Eur Respir J 2003; 22: Suppl. 45, 417s Year: 2003
Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Effects of PKR inhibitor on poly (I:C)-induced exacerbation of severe asthma Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016
LATE-BREAKING ABSTRACT: Induction of granulocyte apoptosis by Bcl-2 inhibitors reduces steroid-insensitive airway inflammation Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016